The molecular imaging and chemotherapy of cancer often depend upon the minute yet deleterious differences between normal cells and their cancerous counterparts. In breast cancer, the expression of the nuclear enzyme topoisomerase-lla (Topo-llo) is one such difference: normal cells carefully regulate their Topo-lla expression levels, while cancerous cells maintain very high levels of the enzyme. Yet despite the preponderance of chemotherapeutic agents that target the enzyme, Topo-lla expression has not yet been exploited in the realm of diagnostic molecular imaging. We propose the design, synthesis, and development of a novel PET radiotracer for the in vivo imaging of topoisomerase levels in breast cancer. All molecular imaging strategies can be broken down into three parts: technique, target, and tracer. In this case, the technique will be positron emission tomography (PET). Over the past 25 years, PET radiotracers have made a tremendous impact in oncology, with agents employed as tracers for processes ranging from blood flow to nutrient consumption. The relationship between the target, Topo-ll, and breast cancer is well documented and profound: in breast cancer alone, Topo-ll levels have been correlated with disease progression, response to chemotherapy, and disease-related death. Finally, the tracers in this study will be radiolabeled copper-thiosemicarbazones (Cu-TSC). An extensive body of research have shown that these complexes specifically target and strongly inhibit Topo-ll, making them a perfect choice for the task at hand. This study has been designed to systematically develop a clinically translatable Cu-(TSC) complex for the quantitative in vivo imaging of Topo-lla expression levels in breast cancer tumors, A three-stage approach will be employed, with the most promising compounds from each phase advancing to the next. First, we will synthesize and characterize a series of candidate Cu-TSC complexes. We will next select those compounds with the most advantageous traits and employ them in in vitro assays with cultured breast cancer cells to further investigate their potential as radiotracers. Finally, the most promising compounds will be screened using small animal PET/CT imaging with in vivo tumor models expressing high and low levels of Topo-lla.

Public Health Relevance

The ultimate goal of this research plan is potentially paradigm-shifting: the development for translation of a positron emission tomography imaging agent that would allow clinicians to explore the levels of the breast cancer biomarker Topo-lla in tumors. Not only would a specific and sensitive 64-Cu-TSC Topo- lla imaging probe have the potential to be a valuable diagnostic tool, it could concomitantly provide a wealth of information that would allow doctors to derive patient-specific treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32CA144138-03
Application #
8126445
Study Section
Special Emphasis Panel (ZRG1-F15-L (20))
Program Officer
Jakowlew, Sonia B
Project Start
2009-09-27
Project End
2012-09-26
Budget Start
2011-09-27
Budget End
2012-09-26
Support Year
3
Fiscal Year
2011
Total Cost
$51,326
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Reiner, Thomas; Zeglis, Brian M (2014) The inverse electron demand Diels-Alder click reaction in radiochemistry. J Labelled Comp Radiopharm 57:285-90
Price, Eric W; Zeglis, Brian M; Cawthray, Jacqueline F et al. (2013) H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy. J Am Chem Soc 135:12707-21
Zeglis, Brian M; Davis, Charles B; Aggeler, Robert et al. (2013) Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjug Chem 24:1057-67
Deri, Melissa A; Zeglis, Brian M; Francesconi, Lynn C et al. (2013) PET imaging with ??Zr: from radiochemistry to the clinic. Nucl Med Biol 40:3-14
Zeng, Dexing; Zeglis, Brian M; Lewis, Jason S et al. (2013) The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. J Nucl Med 54:829-32
Zeglis, Brian M; Sevak, Kuntal K; Reiner, Thomas et al. (2013) A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. J Nucl Med 54:1389-96
Zeglis, Brian M; Divilov, Vadim; Lewis, Jason S (2011) Role of metalation in the topoisomerase II? inhibition and antiproliferation activity of a series of ?-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes. J Med Chem 54:2391-8
Zeglis, Brian M; Lewis, Jason S (2011) A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans 40:6168-95
Zeglis, Brian M; Pillarsetty, NagaVaraKishore; Divilov, Vadim et al. (2011) The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nucl Med Biol 38:683-96